Latest Birchview Capital, LP Stock Portfolio
Birchview Capital, LP Performance:
2024 Q3: 14.03%YTD: 1.51%2023: -17.13%
Performance for 2024 Q3 is 14.03%, and YTD is 1.51%, and 2023 is -17.13%.
About Birchview Capital, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Birchview Capital, LP reported an equity portfolio of $115.2 Millions as of 30 Sep, 2024.
The top stock holdings of Birchview Capital, LP are BMY, BDSX, ACAD. The fund has invested 30.8% of it's portfolio in BRISTOL-MYERS SQUIBB CO and 8.6% of portfolio in BIODESIX INC COM RST.
The fund managers got completely rid off SILK ROAD MEDICAL INC (SILK), EQUITRANS MIDSTREAM CORPORATIO (ETRN) and EXXON MOBIL CORP (XOM) stocks. They significantly reduced their stock positions in HARROW HEALTH INC (HROW), BLUEBIRD BIO INC and OVINTIV INC (OVV). Birchview Capital, LP opened new stock positions in EQT CORPORATION (EQT), TREACE MEDICAL CONCEPTS INC (TMCI) and BLUEPRINT MEDICINES CORP (BPMC). The fund showed a lot of confidence in some stocks as they added substantially to INHIBRX BIOSCIENCES INC, ALPHATEC HOLDINGS INC (ATEC) and KALVISTA PHARMACEUTICALS INC (KALV).
The top stock holdings of Birchview Capital, LP are BMY, BDSX, ACAD. The fund has invested 30.8% of it's portfolio in BRISTOL-MYERS SQUIBB CO and 8.6% of portfolio in BIODESIX INC COM RST.
The fund managers got completely rid off SILK ROAD MEDICAL INC (SILK), EQUITRANS MIDSTREAM CORPORATIO (ETRN) and EXXON MOBIL CORP (XOM) stocks. They significantly reduced their stock positions in HARROW HEALTH INC (HROW), BLUEBIRD BIO INC and OVINTIV INC (OVV). Birchview Capital, LP opened new stock positions in EQT CORPORATION (EQT), TREACE MEDICAL CONCEPTS INC (TMCI) and BLUEPRINT MEDICINES CORP (BPMC). The fund showed a lot of confidence in some stocks as they added substantially to INHIBRX BIOSCIENCES INC, ALPHATEC HOLDINGS INC (ATEC) and KALVISTA PHARMACEUTICALS INC (KALV).
Birchview Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Birchview Capital, LP made a return of 14.03% in the last quarter. In trailing 12 months, it's portfolio return was 4.47%.
New Buys
| Ticker | $ Bought |
|---|---|
| eqt corporation | 1,268,440 |
| treace medical concepts inc | 396,430 |
| blueprint medicines corp | 249,750 |
| alumis inc | 106,800 |
| uniqure nv | 98,600 |
New stocks bought by Birchview Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| inhibrx biosciences inc | 165 |
| alphatec holdings inc | 125 |
| kalvista pharmaceuticals inc | 78.26 |
| castle biosciences inc | 70.59 |
| acadia pharmaceuticals inc | 59.9 |
| coherus biosciences inc | 37.78 |
| travere therapeutics inc | 21.31 |
| docgo inc | 11.96 |
Additions to existing portfolio by Birchview Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| harrow health inc | -51.39 |
| bluebird bio inc | -32.13 |
| ovintiv inc | -29.65 |
| neurocrine biosciences inc | -28.41 |
| elutia inc | -14.85 |
| 2seventy bio inc | -11.22 |
| bristol-myers squibb co | -0.3 |
Birchview Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| silk road medical inc | -4,274,860 |
| equitrans midstream corporatio | -1,726,990 |
| g1 therapeutics inc | -182,400 |
| exxon mobil corp | -673,332 |
Birchview Capital, LP got rid off the above stocks
Sector Distribution
Birchview Capital, LP has about 91.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 91.8 |
| Others | 5.4 |
| Energy | 2.8 |
Market Cap. Distribution
Birchview Capital, LP has about 40.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 40.1 |
| SMALL-CAP | 22.2 |
| MID-CAP | 19.7 |
| MICRO-CAP | 12.1 |
| NANO-CAP | 4.9 |
Stocks belong to which Index?
About 71.2% of the stocks held by Birchview Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 39.3 |
| S&P 500 | 31.9 |
| Others | 28.8 |
Birchview Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Birchview Capital, LP
Birchview Capital, LP has 61 stocks in it's portfolio. About 66.7% of the portfolio is in top 10 stocks. PRTA proved to be the most loss making stock for the portfolio. BMY was the most profitable stock for Birchview Capital, LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACAD | acadia pharmaceuticals inc | 5.34 | 400,400 | 6,158,150 | added | 59.9 | ||
| ALKS | alkermes plc | 1.22 | 50,000 | 1,399,500 | unchanged | 0.00 | ||
| APLS | apellis pharmaceuticals inc | 0.35 | 14,000 | 403,760 | unchanged | 0.00 | ||
| ARVN | arvinas inc | 0.32 | 15,000 | 369,450 | unchanged | 0.00 | ||
| ATEC | alphatec holdings inc | 0.96 | 198,000 | 1,100,880 | added | 125 | ||
| AXDX | accelerate diagnostics inc | 0.48 | 325,239 | 556,158 | unchanged | 0.00 | ||
| AXGN | axogen inc | 2.40 | 197,000 | 2,761,940 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 0.31 | 4,000 | 359,480 | unchanged | 0.00 | ||
| AZYO | elutia inc | 4.37 | 1,321,220 | 5,033,830 | reduced | -14.85 | ||
| BCRX | biocryst pharmaceuticals inc | 0.26 | 40,000 | 304,000 | unchanged | 0.00 | ||
| BDSX | biodesix inc com rst | 8.55 | 5,541,180 | 9,855,090 | unchanged | 0.00 | ||
| BMY | bristol-myers squibb co | 30.81 | 686,182 | 35,503,000 | reduced | -0.3 | ||
| BPMC | blueprint medicines corp | 0.22 | 2,700 | 249,750 | new | |||
| CABA | cabaletta bio inc | 0.04 | 10,000 | 47,200 | unchanged | 0.00 | ||
| CGEM | cullinan oncology inc | 0.29 | 20,000 | 334,800 | unchanged | 0.00 | ||
| CHRS | coherus biosciences inc | 0.34 | 372,000 | 386,880 | added | 37.78 | ||
| CORT | corcept therapeutics inc | 2.97 | 74,000 | 3,424,720 | unchanged | 0.00 | ||
| CSTL | castle biosciences inc | 1.44 | 58,000 | 1,654,160 | added | 70.59 | ||
| CYTK | cytokinetics inc | 0.46 | 10,000 | 528,000 | unchanged | 0.00 | ||
| DCGO | docgo inc | 1.48 | 515,000 | 1,709,800 | added | 11.96 | ||